Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 16/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL18898 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1115700 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL167772 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL140618 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14645374 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL19614558 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14645375 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL579001 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4646147 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4284352 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023090899-A1 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | (주)인벤티지랩 | 2023-05-25 | — | — | WO | claimed |
| WO-2023090899-A1 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | (주)인벤티지랩 | 2023-05-25 | — | — | WO | disclosed |
| CN-1964712-A | Selective androgen receptor modulators and methods of use thereof | UNIV TENNESSEE RES FOUNDATION (US) | 2007-05-16 | — | — | CN | disclosed |
| EP-1587470-A2 | IMPROVED FORMULATIONS FOR TRANSMUCOSAL VAGINAL DELIVERY OF BISPHOSPHONATES | UMD, Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004067063-A2 | IMPROVED FORMULATIONS FOR TRANSMUCOSAL VAGINAL DELIVERY OF BISPHOSPHONATES | UMD, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1311213-A1 | VAGINAL DELIVERY OF BISPHOSPHONATES | UMD, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002009631-A1 | VAGINAL DELIVERY OF BISPHOSPHONATES | UMD, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-1102590-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LTD. (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007598-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LIMITED (GB) | 2000-02-17 | — | — | WO | disclosed |